Arrepath
1 known investors
Arrepath uses machine learning to discover new small-molecule drug classes, treating heterogeneous bioactivity data as a modeling asset to work with small datasets and novel chemistry. Its lead program is an oral small molecule for outpatient urinary tract infections, with a second program targeting non-tuberculous mycobacterial infections, and its platform is built to generalize across therapeutic areas.
AI & Machine LearningBiotechDeep Tech
Investors · 1
Frequently asked questions
- What does Arrepath do?
- Arrepath uses machine learning to discover new small-molecule drug classes, treating heterogeneous bioactivity data as a modeling asset to work with small datasets and novel chemistry. Its lead program is an oral small molecule for outpatient urinary tract infections, with a second program targeting non-tuberculous mycobacterial infections, and its platform is built to generalize across therapeutic areas.
- Who are Arrepath's investors?
- Arrepath's investors include Innospark Ventures.